TA216 Leukaemia (lymphocytic) - bendamustine: review decision - March 2014 information
History
A list of downloadable documents created during development.
Background information
-
-
Appendix A - Decision paper presented to the Institute's Guidance Executive
-
Appendix A - Decision paper presented to the Institute's Guidance Executive (PDF 103 KB)
-
TA216 Leukaemia (lymphocytic) - bendamustine: review proposal - December 2013 information
-
TA216 Leukaemia (lymphocytic) - bendamustine: Appendix A - provisional matrix of stakeholders
-
-
TA216 Leukaemia (lymphocytic) - bendamustine: Appendix B - proposal paper presented to the Institute's Guidance Executive
-
Leukaemia (lymphocytic) - bendamustine: equality impact assessment
-
Leukaemia (lymphocytic) - bendamustine: equality impact assessment
-
Leukaemia (lymphocytic) - bendamustine: equality impact assessment (PDF 20 KB)
Leukaemia (lymphocytic) - bendamustine: final appraisal determination
-
Leukaemia (lymphocytic) - bendamustine: final appraisal determination information
-
Leukaemia (lymphocytic) - bendamustine: final appraisal determination document
-
Leukaemia (lymphocytic) - bendamustine: final appraisal determination document (PDF 228 KB)
-
Leukaemia (lymphocytic) - bendamustine: pre-meeting briefing
-
Leukaemia (lymphocytic) - bendamustine: pre-meeting briefing (PDF 252 KB)
-
Leukaemia (lymphocytic) - bendamustine: final scope and final matrix of comsultees and commentators
-
Leukaemia (lymphocytic) - bendamustine: scope
-
-
Leukaemia (lymphocytic) - bendamustine: matrix
-
-
Leukaemia (lymphocytic) - bendamustine: manufacturer submission
-
Leukaemia (lymphocytic) - bendamustine: manufacturer submission (PDF 3.18 MB)
-
Leukaemia (lymphocytic) - bendamustine: clarification letters
-
Leukaemia (lymphocytic) - bendamustine: NICE request to the manufacturer for clarification on their submission
-
-
Leukaemia (lymphocytic) - bendamustine: manufacturer's response to NICE's request for clarification 1
-
-
Leukaemia (lymphocytic) - bendamustine: manufacturer's response to NICE's request for clarification 2
-
-
Leukaemia (lymphocytic) - bendamustine: patient group, professional group and NHS organisation submissions
-
Leukaemia (lymphocytic) - bendamustine: British Society for Haematology and Royal College of Pathologists (joint submission)
-
-
Leukaemia (lymphocytic) - bendamustine: Chronic Lymphocytic Leukaemia Support Association
-
-
Leukaemia (lymphocytic) - bendamustine: Leukaemia CARE
-
Leukaemia (lymphocytic) - bendamustine: Leukaemia CARE (PDF 34 KB)
-
Leukaemia (lymphocytic) - bendamustine: Lymphoma Association
-
Leukaemia (lymphocytic) - bendamustine: Lymphoma Association (PDF 173 KB)
-
Leukaemia (lymphocytic) - bendamustine: Royal College of Physicians / NCRI / RCR / ACP / JCCO
-
-
Leukaemia (lymphocytic) - bendamustine: United Kingdom Chronic Lymphocytic Leukaemia Forum
-
-
Leukaemia (lymphocytic) - bendamustine: Expert personal perspectives
-
Leukaemia (lymphocytic) - bendamustine: Jane Barnard nominated
-
Leukaemia (lymphocytic) - bendamustine: Jane Barnard nominated (PDF 15 KB)
-
Leukaemia (lymphocytic) - bendamustine: Dr Chris Fegan
-
Leukaemia (lymphocytic) - bendamustine: Dr Chris Fegan (PDF 16 KB)
-
Leukaemia (lymphocytic) - bendamustine: Professor Andrew Pettitt
-
Leukaemia (lymphocytic) - bendamustine: Professor Andrew Pettitt (PDF 14 KB)
-
Leukaemia (lymphocytic) - bendamustine: Chonette Taylor
-
Leukaemia (lymphocytic) - bendamustine: Chonette Taylor (PDF 13 KB)
-
Leukaemia (lymphocytic) - bendamustine: Evidence Review Group report
-
Leukaemia (lymphocytic) - bendamustine: Evidence Review Group report (PDF 1.63 MB)
-
Leukaemia (lymphocytic) - bendamustine: Evidence Review Group report - factual accuracy check
-
Leukaemia (lymphocytic) - bendamustine: response to consultee and commentator comments on the draft scope
-
Leukaemia (lymphocytic) - bendamustine: response to consultee and commentator comments on the draft scope
-
Leukaemia (lymphocytic) - bendamustine: institutes response to consultee and commentator comments on the provisional matrix
-
Leukaemia (lymphocytic) - bendamustine: institutes response to consultee and commentator comments on the provisional matrix
-
Leukaemia (lymphocytic) - bendamustine: final matrix
-
Leukaemia (lymphocytic) - bendamustine: final matrix
-
Leukaemia (lymphocytic) - bendamustine: final matrix (PDF 31 KB)
Leukaemia (lymphocytic) - bendamustine: final scope
-
Leukaemia (lymphocytic) - bendamustine: final scope
-
Leukaemia (lymphocytic) - bendamustine: final scope (PDF 26 KB)
Appendix C - provisional matrix (pre-referral) - November 2009
-
Appendix C - provisional matrix (pre-referral) - November 2009
-
Appendix C - provisional matrix (pre-referral) - November 2009 (PDF 55 KB)
Appendix B - draft scope for consultation (pre-referral) - November 2009
-
Appendix B - draft scope for consultation (pre-referral) - November 2009
-
Appendix B - draft scope for consultation (pre-referral) - November 2009 (PDF 47 KB)